BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 24035575)

  • 21. Phenotypic variability within the inclusion body spectrum of basophilic inclusion body disease and neuronal intermediate filament inclusion disease in frontotemporal lobar degenerations with FUS-positive inclusions.
    Gelpi E; Lladó A; Clarimón J; Rey MJ; Rivera RM; Ezquerra M; Antonell A; Navarro-Otano J; Ribalta T; Piñol-Ripoll G; Pérez A; Valldeoriola F; Ferrer I
    J Neuropathol Exp Neurol; 2012 Sep; 71(9):795-805. PubMed ID: 22892522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration.
    Rohrer JD; Lashley T; Schott JM; Warren JE; Mead S; Isaacs AM; Beck J; Hardy J; de Silva R; Warrington E; Troakes C; Al-Sarraj S; King A; Borroni B; Clarkson MJ; Ourselin S; Holton JL; Fox NC; Revesz T; Rossor MN; Warren JD
    Brain; 2011 Sep; 134(Pt 9):2565-81. PubMed ID: 21908872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative clinical, pathological, biochemical and genetic study of fused in sarcoma proteinopathies.
    Lashley T; Rohrer JD; Bandopadhyay R; Fry C; Ahmed Z; Isaacs AM; Brelstaff JH; Borroni B; Warren JD; Troakes C; King A; Al-Saraj S; Newcombe J; Quinn N; Ostergaard K; Schrøder HD; Bojsen-Møller M; Braendgaard H; Fox NC; Rossor MN; Lees AJ; Holton JL; Revesz T
    Brain; 2011 Sep; 134(Pt 9):2548-64. PubMed ID: 21752791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [History and classification of frontotemporal lobar degeneration].
    Okamoto K
    Brain Nerve; 2009 Nov; 61(11):1203-8. PubMed ID: 19938676
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration.
    Urwin H; Josephs KA; Rohrer JD; Mackenzie IR; Neumann M; Authier A; Seelaar H; Van Swieten JC; Brown JM; Johannsen P; Nielsen JE; Holm IE; ; Dickson DW; Rademakers R; Graff-Radford NR; Parisi JE; Petersen RC; Hatanpaa KJ; White CL; Weiner MF; Geser F; Van Deerlin VM; Trojanowski JQ; Miller BL; Seeley WW; van der Zee J; Kumar-Singh S; Engelborghs S; De Deyn PP; Van Broeckhoven C; Bigio EH; Deng HX; Halliday GM; Kril JJ; Munoz DG; Mann DM; Pickering-Brown SM; Doodeman V; Adamson G; Ghazi-Noori S; Fisher EM; Holton JL; Revesz T; Rossor MN; Collinge J; Mead S; Isaacs AM
    Acta Neuropathol; 2010 Jul; 120(1):33-41. PubMed ID: 20490813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct early symptoms in neuropathologically proven frontotemporal lobar degeneration.
    Kawakami I; Arai T; Shinagawa S; Niizato K; Oshima K; Ikeda M
    Int J Geriatr Psychiatry; 2021 Jan; 36(1):38-45. PubMed ID: 32748432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mixed TDP-43 proteinopathy and tauopathy in frontotemporal lobar degeneration: nine case series.
    Kim EJ; Brown JA; Deng J; Hwang JL; Spina S; Miller ZA; DeMay MG; Valcour V; Karydas A; Ramos EM; Coppola G; Miller BL; Rosen HJ; Seeley WW; Grinberg LT
    J Neurol; 2018 Dec; 265(12):2960-2971. PubMed ID: 30324308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration.
    Cairns NJ; Bigio EH; Mackenzie IR; Neumann M; Lee VM; Hatanpaa KJ; White CL; Schneider JA; Grinberg LT; Halliday G; Duyckaerts C; Lowe JS; Holm IE; Tolnay M; Okamoto K; Yokoo H; Murayama S; Woulfe J; Munoz DG; Dickson DW; Ince PG; Trojanowski JQ; Mann DM;
    Acta Neuropathol; 2007 Jul; 114(1):5-22. PubMed ID: 17579875
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Frontotemporal lobar degeneration proteinopathies have disparate microscopic patterns of white and grey matter pathology.
    Giannini LAA; Peterson C; Ohm D; Xie SX; McMillan CT; Raskovsky K; Massimo L; Suh E; Van Deerlin VM; Wolk DA; Trojanowski JQ; Lee EB; Grossman M; Irwin DJ
    Acta Neuropathol Commun; 2021 Feb; 9(1):30. PubMed ID: 33622418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tau pathology in frontotemporal lobar degeneration with C9ORF72 hexanucleotide repeat expansion.
    Bieniek KF; Murray ME; Rutherford NJ; Castanedes-Casey M; DeJesus-Hernandez M; Liesinger AM; Baker MC; Boylan KB; Rademakers R; Dickson DW
    Acta Neuropathol; 2013 Feb; 125(2):289-302. PubMed ID: 23053135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Frontotemporal lobar degeneration (FTLD) concept and classification update].
    Nakano I
    Rinsho Shinkeigaku; 2011 Nov; 51(11):844-7. PubMed ID: 22277388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuronal intermediate filament inclusion disease may be incorrectly classified as a subtype of FTLD-FUS.
    Bieniek KF; Josephs KA; Lin WL; Dickson DW
    Free Neuropathol; 2020; 1():. PubMed ID: 34386806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinicopathological features of sporadic frontotemporal lobar degeneration with TDP-43-positive inclusions].
    Yokota O
    Rinsho Shinkeigaku; 2010 Nov; 50(11):1018-21. PubMed ID: 21921551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No interaction between tau and TDP-43 pathologies in either frontotemporal lobar degeneration or motor neurone disease.
    Robinson AC; Thompson JC; Weedon L; Rollinson S; Pickering-Brown S; Snowden JS; Davidson YS; Mann DM
    Neuropathol Appl Neurobiol; 2014 Dec; 40(7):844-54. PubMed ID: 24861427
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathological features of FTLD-FUS in a Japanese population: analyses of nine cases.
    Kobayashi Z; Kawakami I; Arai T; Yokota O; Tsuchiya K; Kondo H; Shimomura Y; Haga C; Aoki N; Hasegawa M; Hosokawa M; Oshima K; Niizato K; Ishizu H; Terada S; Onaya M; Ikeda M; Oyanagi K; Nakano I; Murayama S; Akiyama H; Mizusawa H
    J Neurol Sci; 2013 Dec; 335(1-2):89-95. PubMed ID: 24050818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis.
    Mackenzie IR; Neumann M
    Brain Res; 2012 Jun; 1462():40-3. PubMed ID: 22261247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pathomechanisms and clinical aspects of frontotemporal lobar degeneration].
    Bürger K; Arzberger T; Stephan J; Levin J; Edbauer D
    Nervenarzt; 2017 Feb; 88(2):163-172. PubMed ID: 27999880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant interaction between FUS and SFPQ in neurons in a wide range of FTLD spectrum diseases.
    Ishigaki S; Riku Y; Fujioka Y; Endo K; Iwade N; Kawai K; Ishibashi M; Yokoi S; Katsuno M; Watanabe H; Mori K; Akagi A; Yokota O; Terada S; Kawakami I; Suzuki N; Warita H; Aoki M; Yoshida M; Sobue G
    Brain; 2020 Aug; 143(8):2398-2405. PubMed ID: 32770214
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current concepts in the classification and diagnosis of frontotemporal lobar degenerations: a practical approach.
    Rohan Z; Matej R
    Arch Pathol Lab Med; 2014 Jan; 138(1):132-8. PubMed ID: 24377823
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chorea as a clinical feature of the basophilic inclusion body disease subtype of fused-in-sarcoma-associated frontotemporal lobar degeneration.
    Kawakami I; Kobayashi Z; Arai T; Yokota O; Nonaka T; Aoki N; Niizato K; Oshima K; Higashi S; Katsuse O; Hosokawa M; Hasegawa M; Akiyama H
    Acta Neuropathol Commun; 2016 Apr; 4():36. PubMed ID: 27044537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.